ProCE Banner Activity

IMerge Pooled Analysis: Effect of Previous Treatments on Imetelstat Activity in RBC Transfusion–Dependent LR-MDS Relapsed/Refractory to ESAs

Conference Coverage
Slideset

A pooled analysis of the phase II/III and QTc IMerge study in patients with transfusion-dependent lower-risk MDS suggested imetelstat activity regardless of the type or number of previous treatments.

Released: December 10, 2024

Expiration: December 09, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation